Top Page
Serina Therapeutics
(NYSE MKT:SER)
Serina Therapeutics (SER) vs. S&P 500 (SPY)
Serina Therapeutics Business Overview & Revenue Model
Serina Therapeutics Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 56.00K | 142.00K | 500.00K | 3.04M | 54.00K | 1.73M | Gross Profit |
| -26.00K | -29.00K | 355.00K | 2.89M | -1.23M | 729.50K | EBIT |
| -17.05M | -9.96M | -2.27M | -1.63M | -10.41M | -12.56M | EBITDA |
| -5.06M | -9.78M | -2.60M | -1.59M | -8.74M | -11.61M | Net Income Common Stockholders |
| -5.56M | -14.80M | -2.68M | -1.26M | -10.87M | -12.15M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 8.52M | 345.00K | 532.23K | 1.31M | 527.00K | 2.35M | Total Assets |
| 10.63M | 11.96M | 858.04K | 1.84M | 3.92M | 7.44M | Total Debt |
| 0.00 | 4.37M | 1.81M | 398.17K | 6.30M | 1.96M | Net Debt |
| -8.52M | 4.02M | 1.28M | 83.33K | 5.77M | -396.00K | Total Liabilities |
| 1.66M | 6.61M | 38.64M | 36.95M | 9.32M | 4.83M | Stockholders Equity |
| 8.01M | 5.47M | -37.78M | -35.11M | -5.12M | 2.22M |
| Cash Flow | Free Cash Flow | ||||
| -17.16M | -7.80M | -2.09M | -2.36M | -7.84M | -10.80M | Operating Cash Flow |
| -17.14M | -7.80M | -2.08M | -2.25M | -7.82M | -10.16M | Investing Cash Flow |
| -22.00K | -10.00M | 980.94K | 823.32K | -20.00K | -361.00K | Financing Cash Flow |
| 13.21M | 17.50M | 1.31M | 1.08M | 5.96M | 6.26M |
Serina Therapeutics Technical Analysis
Serina Therapeutics Risk Analysis
Serina Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $5.28B | 22.63 | 19.71% | ― | 52.97% | ― | |
64 Neutral | $128.67B | ― | -3.15% | ― | 11.64% | -114.72% | |
58 Neutral | $7.11B | ― | -1.30% | ― | 0.33% | -171.08% | |
50 Neutral | $29.98B | ― | -414.62% | ― | 22.97% | 38.54% | |
50 Neutral | $5.51B | 2.95 | -43.70% | 2.78% | 16.94% | 3.59% | |
49 Neutral | $4.51B | ― | -93.03% | ― | -10.48% | -18.79% | |
43 Neutral | $50.65M | ― | 45.59% | ― | 34.04% | 55.34% |
Serina Therapeutics Corporate Events
On April 15, 2025, Serina Therapeutics announced that its Chief Development Officer, Dr. Randall Moreadith, presented at the LNP Formulation & Process Development Summit in Boston. The presentation highlighted a significant advancement in lipid nanoparticle (LNP) technology, where the company has identified a PEOZ-lipid capable of replacing the PEG-lipid in standard LNP formulations. This breakthrough addresses the high incidence of anaphylaxis associated with PEG-lipids in mRNA vaccines and other therapies, potentially improving safety and efficacy for patients.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Neutral.
Serina Therapeutics’ overall stock score is primarily hindered by severe financial challenges, including declining revenue, high liabilities, and negative cash flow. Although there is some short-term technical momentum, the valuation is weak due to negative earnings. Positive corporate developments and strategic initiatives are noted but do not offset the fundamental financial concerns.
To see Spark’s full report on SER stock, click here.
On April 8, 2025, Serina Therapeutics announced a $5 million private placement of securities to support the development of SER-252, its lead candidate for advanced Parkinson’s disease. This funding will aid in initiating a Phase 1 clinical trial for SER-252, which uses Serina’s POZ technology to provide continuous dopaminergic stimulation, potentially offering significant benefits to patients.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Neutral.
Serina Therapeutics’ overall stock score is primarily hindered by severe financial challenges, including declining revenue, high liabilities, and negative cash flow. Although there is some short-term technical momentum, the valuation is weak due to negative earnings. Positive corporate developments and strategic initiatives are noted but do not offset the fundamental financial concerns.
To see Spark’s full report on SER stock, click here.
On April 7, 2025, Serina Therapeutics announced that its CEO, Steve Ledger, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025. The presentation will highlight the company’s advancements, particularly the POZ Platform and the upcoming clinical trial of SER-252 for Parkinson’s disease. This announcement underscores Serina’s strategic positioning in the biotechnology sector and its potential impact on treatment options for Parkinson’s disease, with SER-252 projected to achieve significant market success.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, (SER) is a Neutral.
Serina Therapeutics’ stock score is primarily hindered by its severe financial challenges, including declining revenue, high liabilities, and negative cash flow. While there is some short-term technical momentum, the overall valuation is weak due to negative earnings. Positive corporate developments and strategic initiatives are noted but do not offset the fundamental financial concerns.
To see Spark’s full report on (SER) stock, click here.
On March 24, 2025, Serina Therapeutics announced that its Chief Development Officer, Randall Moreadith, presented new data at the American Chemistry Society Spring 2025 Meeting. The presentation highlighted the non-immunogenic profile of Serina’s POZ-lipid technology, which did not trigger an antibody response in rats, unlike the commonly used PEG-lipid standards. This discovery could lead to safer and more effective lipid nanoparticle formulations for gene therapy and RNA-based medicines, potentially impacting the development of treatments that avoid adverse immune reactions.
On February 11, 2025, Serina Therapeutics announced the appointment of Dr. Jay Venkatesan to its Board of Directors, effective February 12, 2025. Dr. Venkatesan, who has extensive experience in biotechnology investments and strategic growth, will also serve as the Audit Committee Chair. His appointment is expected to bolster Serina’s strategic vision as the company leverages its POZ Platform to develop innovative therapeutics. Concurrently, co-founder Dr. Milton Harris will transition to Director Emeritus and Chair of the Scientific Advisory Board, continuing to guide the company’s research efforts.
On February 3, 2025, Serina Therapeutics announced the completion of a second $5 million tranche of a $10 million financing deal with JuvVentures, supporting the progression of SER-252 into Phase 1 clinical trials for advanced Parkinson’s disease in late 2025. This capital injection, achieved by issuing shares at a 113% premium, underlines Serina’s commitment to its innovative drug delivery platform and enhances its market positioning by potentially offering significant benefits in Parkinson’s treatment.
On January 14, 2025, Serina Therapeutics announced the appointment of Karen J. Wilson to its Board of Directors, marking a significant addition due to her extensive experience in the life sciences sector. Wilson’s financial and industry expertise is expected to support Serina’s strategic initiatives and enhance its positioning in the biotechnology market. Concurrently, Steven Mintz departed from the board, with Remy Gross taking over as the chair of the Audit Committee.